Strategic Executive Leadership Changes
Daiichi Sankyo Restructures Leadership to Accelerate Global Oncology and Specialty Medicine Commercialization
Daiichi Sankyo, a major pharmaceutical company, has restructured its executive leadership to sharpen focus on cancer and specialty medicine sales globally. The company created a new Chief Commercialization Officer position and appointed Ken Keller, who spent five years building U.S. and European oncology operations, to lead the role Market Screener. The reorganization establishes a five-region business structure designed to accelerate growth across key markets.
Ken Keller Takes New Chief Commercialization Officer Role
Ken Keller, who joined Daiichi Sankyo in 2014, now leads the newly created Chief Commercialization Officer position Market Screener. He previously served as Head of Global Oncology Business for five years. In that role, he built commercial teams across the United States and Europe. Keller's appointment reflects the company's priority: growing its cancer drug business worldwide through coordinated sales and marketing efforts.
New Five-Region Structure Replaces Old Business Model
Daiichi Sankyo introduced a centralized Commercialization Unit organized into five regional divisions Market Screener. This replaces the previous structure. The new model aims to support each region's unique market conditions and regulatory requirements. The company believes the tighter coordination will help oncology drugs reach more patients faster and more efficiently across continents.
Regional Leaders Named to Drive European and Asian Expansion
Markus Kosch, MD, will lead the Europe Business starting April 1, 2027, as the region's General Manager within the Commercialization Unit Market Screener. Yuichi Yomasu, currently heading the ASCA (Asia, South and Central America) Business Unit, will focus specifically on growing sales in China. Marcelo Goncalves takes charge of Latin America, covering Brazil, Colombia, and Mexico Market Screener. Each appointment targets high-growth markets for the company's specialty medicines.
Long-Tenured Executive Nobuo Murakami Concludes Four-Decade Career
Nobuo Murakami, who spent 40 years at Daiichi Sankyo, is departing the company as the reorganization takes effect Market Screener. His departure marks the end of a lengthy tenure. The leadership changes signal a generational shift toward executives with global commercial expertise in oncology and specialty medicine.
Sentiment
NeutralPublishers
3
Articles
2
Reach
4
